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esponsibility of Xi’Abstract Chromatographic behavior of co-eluted compounds from un-extracted drug-free plasma
samples was studied by LC–MS and LC–MS/MS with positive APCI. Under soft gradient, total ion
chromatogram (TIC) consisted of two major peaks separated by a constant lower intensity region. Early
peak (0.15–0.4 min) belongs to polar plasma compounds and consisted of smaller mass ions (m/zo250);
late peak (3.6–4.6 min) belongs to thermally unstable phospholipids and consisted of fragments with
m/zo300. Late peak is more sensitive to variations in chromatographic and MS parameters. Screening of
most targeted cardiovascular drugs at levels lower than 50 ng/mL has been possible by LC–MS for drugs
with retention factors larger than three. Matrix effects and recovery, at 20 and 200 ng/mL, were evaluated
for spiked plasma samples with 15 cardiovascular drugs, by MRM–LC–MS/MS. Average recoveries were
above 90% and matrix effects expressed as percent matrix factor (% MF) were above 100%, indicating
enhancement character for APCI. Large uncertainties were signiﬁcant for drugs with smaller masses
(m/zo250) and retention factors lower than two.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Else
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an Jiaotong University.1. Introduction
Screening, identiﬁcation and quantiﬁcation of drugs in biological
samples remain a continuous challenging task for bio-analysis.
Analysis of a large number of samples in short time (pharmaco-
kinetic studies) and screening for a large number of drugs and
metabolites in small samples (systematic toxicological analysisvier B.V. All rights reserved.
Co-eluted plasma compounds by APCI-LC-MS(/MS) 385(STA)) necessitate continuous development of methods with
adequate sensitivity, selectivity and short run time.
Methods, based on LC–MS and LC–MS/MS are currently the
methods of choice for pharmaceutical and clinical analysis due to
high sensitivity and selectivity. A most reliable method combines
optimized extraction with careful selection of LC and MS parameters.
Recent advances in LC–MS(/MS) were reviewed by many
authors [1–3]. Peters [1] provided an overview on recent devel-
opments of LC–MS(/MS)-based analysis in clinical and forensic
toxicology focusing on STA and multi-analyte procedures. He
concluded that hybrid mass spectrometers and high resolution time
of ﬂight mass spectrometers (TOF-MS) are essential to generating
rich product ion spectra that can be searched against libraries
of reference spectra, and for screening of compounds without
reference standards. Maurer [2] reviewed multi-analyte procedures
for screening and quantiﬁcation of drugs in blood and plasma by
LC–MS and LC–MS/MS. He concluded that cost issues and
irreproducibility of ionization are still limitations for LC–MS/MS
to become the gold technique in clinical and toxicological and
doping control. Numerous methods for targeted analytes such as
amphetamines, opiates and therapeutic drugs were reported [4–9].
Gonzalez et al. [4] reported an LC–MS/MS method for quantiﬁca-
tion of 55 drugs prescribed in combined cardiovascular therapy.
Krichherr et al. [5] reported quantitative analysis of 48 antide-
pressant and antipsychotics in serum by LC–MS/MS. Matrix
effects from co-eluted endogenous sample compounds were
addressed in all previous reviews and methods.
Matrix effect (ME) is deﬁned as the direct and indirect alteration or
interference in response due to the presence of unintended analytes or
other interfering substances in the sample [10,11]. In LC–MS/MS
methods, ionization and non-ionization matrix effects are familiar.
Ionization matrix effects refer to the ionization suppression or
enhancement caused by co-eluted extracted substances from the
biological matrix [12]. Non-ionization matrix effect refers to mainly
loss of analyte during sample preparation and separation steps.
Ionization matrix effects dominate assuming an efﬁcient extraction
method (clean up) preceded injection of the sample; however, non-
ionization matrix effects should not be ignored, especially when un-
extracted samples were employed [12].
Perspectives in addressing matrix effects, and recovery issues in
regulated drug bioanalysis by LC–MS/MS were reviewed [12,13].
Liang [13] examined key issues related to ionization matrix effects
and evaluated various methods to address matrix effect problems
with effectiveness and practicality. Huang et al. [12] emphasized
that in LC–MS/MS methods, the cause of assay bias from sources
of matrix is mainly due to an ionization change; however, extrac-
tion recovery may cause analytical assay variation. He proposed
using the term “matrix variation” rather than ME.
The Crystal City conference report [14] and the European
Medicines Agency ﬁnal bioanalysis method validation (BMV)
guidance [11] adapted matrix factor (MF), deﬁned as a ratio of the
analyte peak response in the presence of matrix ions (post-spiked)
to the analyte response in the absence of matrix ions (neat
standards), for quantitative measurements of ionization ME.
Matuszewski et al. [15] suggested ME (%)¼100MF. An ME
of 100 implies no suppression or enhancement matrix effects
ionization. A value either less or more than 100 suggests either
ionization suppression or enhancement.
Recovery assessment (non-ionization matrix effects) usually
accompanies ME assessment, even with un-extracted samples. FDA
guidance, deﬁnes recovery as the percentage ratio of detector response
of pre-spiked blank versus that of post-spiked blank. Pre-spikedanalyte refers to analyte spiked into blank plasma before extrac-
tion, while, post-spiked analyte refers to analyte spiked into blank
plasma extract.
Matrix effects evaluation and reduction was the subject of many
papers. [16–20]. Chambers et al. [16] presented systematic com-
prehensive strategy that optimizes sample preparation and chro-
matography to minimize matrix effects in bioanalytical LC–MS/
MS analysis. Van Eeckhaut et al. [17] reviewed the assessment,
reduction and evaluation of matrix effects during validation of bio-
analytical methods. They emphasized ionization effects as the
main reason for matrix effects. They recommended that evaluation
of matrix effect should be a mandatory part of the validation
procedure for all LC–MS based methods. Matrix effect studies in
most published papers were performed on extracted plasma
samples in ESI mode and in conjunction with targeted analytes.
To our knowledge, few publications dealt with the behavior and
matrix effect of plasma endogenous compounds only [21,22].
In this work we studied the chromatographic behavior of co-
eluted compounds from un-extracted plasma samples and their
effects on screening of drugs by LC–MS(/MS) with atmospheric
pressure chemical ionization (APCI). Our results emphasized the
dependence of matrix effects on m/z of molecular ions and
retention factors of drugs. Eluted drugs with retention factors
larger than three could be screened by single stage LC–MS at levels
lower than 50 ng/mL. Lower matrix effects and larger recoveries
were observed for drugs with molecular ions m/z larger 300 and/or
retention factors larger than 3 under MS/MS conditions.2. Experimental
2.1. Chemicals and reagents
Studied drugs presented in Tables 1 and 2 were generously provided
by International Pharmaceutical Research Center (IPRC) (Amman,
Jordan). HPLC-grade acetonitrile, formic acid, ammonium formate
and other reagents were purchased from Sigma Aldrich (St. Louis,
MO, USA). Water puriﬁed by the use of Millipore Milli-Q system
(Lemount, Switzerland) was used for preparation of all solutions.
Six different batches of drug-free plasma from healthy volunteers (3
males and 3 females; age between 18 and 25 years) were obtained
from King Abdullah Hospital (Irbid, Jordan).
2.2. LC–MS/MS apparatus and conditions
HPLC analysis was carried out on an Agilent 1200 series (Palo
Alto, CA, USA) system consisting of a quaternary pump and
vacuum degasser and a refrigerated autosampler (5 1C). Chromato-
graphy was performed on a 50 mm 4.6 mm, 5-mm particle
(chromatographic behavior) and 50 mm 2.1 mm, 5-mm particle
(ME and recovery) Agilent C18 columns at room temperature.
The mobile phase consisting of solvent A (0.1% (v/v) aqueous
formic acid with 1.0 mM ammonium formate) and solvent B (0.1%
(v/v) formic acid with 1.0 mM ammonium formate in acetonitrile)
was delivered at a ﬂow rate of 0.60 mL/min. The applied LC
gradient was the following: 0–1.0 min 20% B; 1–5.0 min 20–95%
B, 5.0–7.0 min 95% B, 7.0–7.5 min 95–20% B, 7.5–9 min 20% B.
Detection was carried out using an API 3200 triple quadrupole
tandem mass spectrometer (AB Sciex, Darmstadt, Germany) equipped
with a Turbo V source to produce ions from liquid samples. The
Turbo V source can use the TurboIonSpray probe (ESI) or the APCI
probe. The APCI probe source was operated in the positive mode at
Table 2 Percentage matrix effects (ME) and extraction recovery for studied drugs and their MRM analysis conditions.a




Metformin 130.1-71.1 20 0.28 150.176.8 78.5710.8
200 145.673.4 93.276.5
Aspirin 181.2-91.2 20 0.32 147.679.8 86.779.5
200 145.676.7 93.674.5
Propranolol 260.3-155.2 20 3.99 96.375.6 95.375.9
200 95.772.3 94.374.9
Trimethoprim 267.2-166.1 20 0.32 132.379.8 89.676.5
200 128.676.7 91.373.8
Gliclazide 324.3-127.2 20 5.07 118.276.7 87.677.5
200 113.575.2 91.374.5
Enalapril 377.2-234.2 20 4.01 98.675.7 110.2711.3
200 103.272.5 106.779.5
Lisinopril 406.2-246.2 20 0.35 147.3715.3 75.379.5
200 140.879.6 81.677.8
Ramipril 417.3-234.3 20 4.33 98.673.4 87.676.6
200 99.472.8 97.674.3
Valsartan 436.2-207.2 20 5.07 106.879.5 97.674.3
200 96.874.6 93.475.2
Rosuvastatin 482.1-258.3 20 4.79 126.377.5 95.674.5
200 118.974.8 97.272.3
Glimepiride 491.4-126.3 20 5.46 136.079.5 104.479.8
200 128.677.5 104.476.5
Glipizide 494.3-169.2 20 5.38 129.476.7 89.776.9
200 118.375.4 91.372.6
Telmisartan 515.2-497.3 20 4.44 117.576.8 97.672.8
200 114.373.9 94.274.2
Atorvastatin 559.6-440.3 20 5.35 128.6711.5 89.676.6
200 122.477.5 91.473.8
Cand. Cilex. 611.3-423.5 20 6.06 126.878.9 91.379.8
200 121.476.6 96.476.5
aFive replicates at each nominal concentration
Table 1 Retention times and signal-to-noise ratios (S/N) for eight drugs separated by LC–MS in post-spiked
plasma sample (50 ng/mL of each drug).
Drug Molecular ion (MþH)þ Retention time
(min)
Signal-to-noise ratio (S/N) LOQ
(ng/mL)
TIC XIC
Propranolol 260.3 4.16 – 87.5 6.2
Gliclazide 324.2 5.25 20.3 60.7 8.3
Enalapril 377.2 4.23 – 45.6 10.8
Ramipril 417.2 4.60 12.5 75.3 7.1
Rosuvastatin 482.1 4.98 45.3 68.3 7.7
Glimepiride 491.2 5.65 6.5 25.3 17.5
Atorvastatin 559.6 5.54 17.5 71.2 7.2
Cand. Cilex. 611.3 6.23 18.7 75.3 7.1
TIC¼ total ion chromatogram. XIC¼extracted ion chromatogram. LOQ¼ limit of quantitation.
Y.R. Tahboub386
Co-eluted plasma compounds by APCI-LC-MS(/MS) 387450 1C with a needle current of 4.0 mA. Nitrogen was used as curtain
gas (CUR) (10 psi) and gas 1 (70 psi). Analysis was performed by
either Q1-scan (MS) mode or multiple reaction monitoring (MRM)
mode (MS/MS). For Q1-scan mode declustering potential (DP) was
set at 50 V, entrance potential (EP) 5 V and collision entrance
potential (CEP) 20 V. Additionally, for MRM transitions, collision
gas (CAD) was set at 6 psi, collision energy (CE) 35 V, collision cell
exit potential (CXP) 3.0 V and dwell time 50 ms for each MRM
transition and 5 ms pause. Data processing and system control were
performed by Analyst 1.5 software (Applied Biosystems).2.3. Standard solutions
Standard stock solutions of 0.50 mg/mL of each drug in Tables 1
and 2 were prepared separately in methanol. For LC–MS experi-
ments, a stock solution mixture (5.00 mg/mL) of drugs in Table 1
was prepared by transferring 100 mL of each drug solution into a
10 mL volumetric ﬂask, then diluting to the mark with 20%
acetonitrile solution. A working solution mixture (200 ng/mL) was
prepared daily from the stock solution mixture by sub-sequent
dilution with 20% actonitrile solution. For LC–MS/MS experiments,
a stock solution mixture (5.00 mg/mL) of drugs in Table 2 was
prepared by the same way as in LC–MS. Working solution mixtures
(80 and 800 ng/mL) were prepared daily from the stock solution
mixture by sub-sequent dilution with 20% actonitrile solution.2.4. Sample preparation
Plasma was prepared from whole blood as follows: Blood samples
were collected into tubes containing EDTA; then centrifuged at
1.3g for 10 min at 4 1C. The plasma supernatant was carefully
separated from blood cells and collected in polypropylene tubes to
be frozen at 20 1C until analysis [4].
Blank solution was prepared by transferring 200 mL drug-free
human plasma to a 2.00 mL Eppendrof tube, followed by 800 mL
of 20% acetonitrile solution, vortexed for 30 s, and the slightly
turbid solution was centrifuged at 13,000 rpm for 5 min. Pre-
spiked solutions were prepared by transferring 200 mL drug-free
human plasma to a 2.00 mL Eppendrof tube, followed by 50 mL
of drug mixture, vortexed for 30 s, followed by 750 mL of 20%
acetonitrile solution, vortexed for 30 s, and the slightly turbid
solution was centrifuged at 13,000 rpm for 5 min. Post-spiked
solutions were prepared by transferring 200 mL drug-free human
plasma to a 2.00 mL Eppendrof tube, followed by 750 mL of 20%
acetonitrile solution, vortexed and centrifuged in the same manner.
To supernatant 50 mL of drug mixture was added and vortexed
again for 30 s. Nominal concentrations were calculated based on
the volume of plasma (200 mL). Neat standards were prepared by
diluting 50 mL of working standards to 1.00 mL with 20%
acetonitrile solution. Injected concentrations were ﬁve times lower
than nominal concentrations. A 200 mL of each solution was
transferred into a clean 96-deep well plate and 10 mL were injected
into the LC–MS/MS system.2.5. Matrix effects and recovery evaluation
Matrix effects and recovery for each spiked drug in the mixture were
determined at two nominal concentrations (20 and 200 ng/mL).
Analyte concentrations were selected to contain reported concentra-
tions for clinical studies.Recovery (or extraction efﬁciency) was determined by measur-
ing the response of an extracted sample (pre-spiked) against the
response of a post-extracted spiked sample:





Matrix effects (ME) was measured by referring the response of








where A is the response of neat standards, B is the response of post-
spiked samples and C is the response of pre-spiked samples. These
equations are similar to those reported by Matuszewski et al. [15].3. Results
The TIC–LC–MS chromatogram for a drug-free plasma sample
under conditions speciﬁed in experimental section is presented in
Fig. 1A. Co-eluted plasma compounds were distributed over two
major peaks, separated by a middle region with relatively steady
background level. The early peak representing polar compounds
was eluted at tr1¼0.60 min with width at half maxima, W1/2(1)¼
0.20 min. The late peak representing semi- and non-polar com-
pounds was eluted at tr2 (average)¼4.24 min with W1/2(2)¼
0.90 min. When ﬂow rate was increased from 0.60 mL/min to
1.0 mL/min (Fig. 1B), both retention times were decreased (tr1¼
0.37, tr2¼3.20 min). When acetonitrile was replaced by methanol
in mobile phase (Fig. 1C), the early peak was not affected, while
retention time and broadness of late peak were signiﬁcantly
increased (tr2¼6.20 min, W1/2(2)¼1.20 min). When pH of the
mobile phase was increased from 2.87 (0.1% formic acid) to 4.50
(10 mM ammonium formate) (Fig. 1D), the early peak was not
affected, while retention time for the late peak increased from 4.24
to 5.06 min. No signiﬁcant change in either retention times or
broadness of both peaks was observed when column temperature
was raised from ambient to 40 1C (Fig. 1E). A signiﬁcant
broadness of early peak was observed when the APCI probe
temperature was decreased from 450 1C to 400 1C (Fig. 1F). When
a hard gradient was applied (0–1.0 min 70% B, 1–5.0 min 70–95%
B, 5.0–7.0 min 95% B, 7.0–7.5 min 95–70% B, 7.5–9 min 70% B)
(Fig. 1G), a large decrease in retention time of late peak was
observed (tr2¼1.94 min). When the 50 mm 4.6 mm diameter
column was replaced by a 50 mm 2.1 mm diameter column,
a tremendous decrease in retention time and broadness of both
peaks was observed (Fig. 1H) (tr1¼0.20 min, W1/2(1)¼0.10 min;
tr2¼3.76 min, W1/2(2)¼0.25 min). Thus, for subsequent studies a
50 mm 2.1 mm diameter column was employed.
Fig. 2 presents selected APCI mass spectra from selected regions of
Fig. 1H. The representative MS of early peak at 0.232 min (Fig. 2A)
consists of ions with m/zo250, which are attributed to co-eluting polar
plasma compounds. Drugs such as metformin and aspirin elute in this
region. Thus, these drugs could not be determined by LC–MS. Also,
when determined by MRM–LC–MS/MS they are expected to suffer
larger matrix effects (Table 2). However, most therapeutic drugs have
molecular ions m/z (MþH)þ4250 or elute at retention times larger
than 0.30 min. The MS representing middle region at 1.947 min
(Fig. 2B) has the same ion proﬁle as of Fig. 2A, but with ion intensities
10 times less than in Fig. 2A. The MS shown in Fig. 2C at 3.773 min
is a representative of phospholipids late peak. Even phospholipids have
Fig. 1 (A) TIC–LC–MS chromatogram for drug-free plasma collected under: Gradient: 0–1.0 min 20% B, 1–5.0 min 20–95% B, 5.0–7.0 min
95% B, 7.0–7.5 min 95–20% B, 7.5–9 min 20% B; ﬂow rate 0.60 mL/min; pH¼2.87; temperature: ambient; APCI probe temperature¼450 1C;
column: 50 mm 4.6 mm, 5-mm particle. (B) The TIC–LC–MS chromatogram upon increasing ﬂow rate to 1.0 mL/min. (C) The TIC–LC–MS
chromatogram upon replacing acetonitrile with methanol. (D) The TIC–LC–MS chromatogram upon increasing pH from 2.87 to 4.5. (E) The
TIC–LC–MS chromatogram upon increasing column temperature from ambient to 40 1C. (F) The TIC–LC–MS chromatogram upon decreasing
APCI probe temperature from 450 to 400 1C. (G) The TIC–LC–MS chromatogram upon employing a gradient: 0–1.0 min 70% B, 1–5.0 min 70–
95% B, 5.0–7.0 min 95% B, 7.0–7.5 min 95–70% B, 7.5–9 min 70% B. (H) The TIC–LC–MS chromatogram upon replacing the 50 mm 4.6
mm, 5-mm particle column by a 50 mm 2.1 mm, 5-mm particle column.
Y.R. Tahboub388large molar masses m/z4500, the MS consists of ions with m/z
o300 indicating thermal instabilities of phospholipids under APCI.
Thus, drugs eluting in this region usually have molecular ions m/z
(MþH)þ4300 and could be easily screened by single LC–MS.
Similar MS collected under ESI is much complicated and consists of
ions with m/z4500 with relatively high intensities [13].
Fig. 3A presents a TIC–LC–MS chromatogram for eight ther-
apeutic drugs spiked at 50 ng/mL each. These drugs are usually
prescribed for patients with cardiovascular diseases such as diabetes
and hypertension. Extracted ion chromatograms (XIC)–LC–MS
chromatograms at corresponding molecular ions are shown in Fig. 3B.
Table 1 presents retention time and signal-to-noise ratio (S/N) for
each drug calculated from TIC chromatogram and corresponding
XIC. S/N ratios from XICs, as expected, are much higher and LOQs
are much lower. However, TIC peaks usually contain major
fragment ions in addition to molecular ion, which may help inidentiﬁcation in non-targeted screening. S/N ratios from TIC for
propranolol and enalapril could not be calculated due to overlapping
between their TIC peaks. Limits of quantitation (LOQs) calculated
from XICs varied between 6.2 ng/mL for propranolol and 17.5 ng/
mL for glimepiride.
Fig. 4 presents MRM–LC–MS/MS chromatograms for 15 drugs
spiked to a drug-free plasma sample at 20 ng/mL each. These drugs
include the eight drugs studied in LC–MS (Fig. 3, Table 1). Eluted
drugs have retention times either similar to early plasma peak (4
drugs) or late plasma peak (8 drugs). Table 2 presents MRM
transitions, % ME and % recovery at two nominal concentrations 20
and 200 ng/mL. Most drugs show % ME larger than 100, indicating
enhancement character of APCI. Recoveries of most tested drugs are
around 100%, which is expected since sample preparation was
dilution of plasma sample with 20% acetonitrile solution (initial
composition of mobile phase) with a ratio 1:4.
Fig. 3 (A) TIC–LC–MS chromatogram for drug-free plasma sample post-spiked with eight drugs (50 ng/mL) each as follows: 1. Propranolol; 2.
Enalapril; 3. Ramipril; 4. Rosuvastatin; 5. Gliclazide; 6. Atorvastatin; 7. Glimepiride; 8. Candesartan Cilexetil. (B) XIC chromatograms for the
eight drugs (overlaid) from the TIC chromatogram. Molecular ions are presented in Table 1.
Fig. 2 Mass spectra collected from drug-free plasma sample TIC–LC–MS chromatogram (Fig. 1H) at (A) 0.232 min (early peak), (B) 1.947 min
(middle region) and (C) 3.773 min (late peak).
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Fig. 4 MRM–LC–MS/MS chromatograms for drug-free plasma sample post-spiked with ﬁfteen drugs (20 ng/mL) each as follows: A. Metformin;
B. Aspirin; C. Propranolol; D. Trimethoprim; E. Gliclazide; F. Enalapril; G. Lisinopril; H. Ramipril; I. Valsartan; J. Rosuvastatin; K. Glimepiride;
L. Glipizide; M. Telmisartan; N. Atorvastatin; O. Candesartan Cilexetil. Transitions are summarized in Table 2.
Y.R. Tahboub390A selectivity study on six different drug-free plasma samples from
healthy volunteers was performed. The MRM chromatograms did not
show interfering peaks within retention times of selected drugs.4. Discussion
To give this study a perspective, the following points have to be
emphasized: Our major objective was to study the chromatographic
behavior of co-eluting plasma compounds and their effects on
screening of drugs under APCI-LC–MS(/MS). Thus, the sample
preparation procedure was simple and just mixing plasma sample
with initial concentration of mobile phase gradient to prevent
precipitation inside the column. The choice of short RP column
(50 mm) is similar to most published methods for drugs screening,
and to allow maximum co-elution of plasma compounds within
reasonable run-time. Selection of drugs for matrix effects and
recovery studies considered coverage of a wide range of molecular
ions and retention factors. Also, we acknowledge that APCI is not
the ﬁrst choice in bio-analysis and most of the applications are using
ESI accompanied with a proper cleanup method.
Matrix effects of co-eluting plasma compounds are considered
the major setback on LC–MS/MS methods for screening of residues
of drugs in plasma. Lack of selectivity in ionization process between
analytes, mobile phase constituents and co-eluting matrixcompounds created non-linearity and irreproducibility problems
due to suppression and enhancement in analytical signals [1–3].
Recent reported analytical methods were devoted to reduction and
compensation of matrix effects including optimization of novel
extraction methods and employment of sophisticated expensive MS
systems.
Our results indicated that understanding the chromatographic
behavior of co-eluting matrix components could help in screening
and determination of many classes of drugs, especially for targeted
drugs, with minimum sample preparation under APCI.
APCI produces small mass fragments (Fig. 2A–C), indicating
thermal instability of plasma compounds. The elution proﬁle of
plasma compounds includes a region with low ion intensity
between the polar and non-polar peaks. Chromatographic condi-
tions could be optimized to elute analytes in this region where they
are expected to experience higher recovery and lower matrix
effects. Single stage LC–MS (Q1 scan) methods could be
employed to screen most of popular therapeutic and illicit drugs
at moderate concentrations (o50 ng/mL). Acceptable matrix
effect and recovery results were obtained for the 15 drugs analyzed
by MRM–LC–MS/MS over a wide concentration range of 20–
200 ng/mL (Table 2).
Our results also supported enhancement character of APCI [23],
which is believed that co-eluting plasma compounds stabilize
analyte molecular ion and minimize its fragmentation before going
to Q2 for collision induced dissociation.
Co-eluted plasma compounds by APCI-LC-MS(/MS) 391Even the objectives of this study were achieved, a proper
extraction method is still recommended to keep good performance
of separation column for longer periods and to avoid cross-
contamination, especially for screening a large number of drugs
at lower concentrations.5. Conclusions
This paper presented a systematic study of behavior of co-eluting
plasma compounds and their effect on determination of drugs by
APCI-LC–MS(/MS). The LC–MS chromatogram of drug-free
plasma was simple and consisted of two major peaks separated
by a region composed of low-intensity small mass ions. A case
study of spiking ﬁfteen selected drugs with wide range of
protonated molecular ions, (MþH)þ, and retention factors pro-
vided acceptable recovery and matrix effects results by LC–MS/
MS in MRM mode, and the possibility of their screening at
moderate concentrations (o50 ng/mL) by XIC–LC–MS.
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